# Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands

> **NCT06685978** · PHASE3 · RECRUITING · sponsor: **Tasly Pharmaceutical Group Co., Ltd** · enrollment: 430 (estimated)

## Conditions studied

- Hyperplasia of Mammary Glands

## Interventions

- **DRUG:** Xiang Ju Ru Pi Ning capsule Placebo
- **DRUG:** Xiang Ju Ru Pi Ning capsule

## Key facts

- **NCT ID:** NCT06685978
- **Lead sponsor:** Tasly Pharmaceutical Group Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-26
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-07-31
- **Target enrollment:** 430 (ESTIMATED)
- **Last updated:** 2024-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06685978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06685978, "Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06685978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*